Table 2:

Summary of average susceptibility (χ), average R2* values, and average volume for each selected ROI

	χ (ppm) ± SE		R2* (s⁻¹) ± SE		Corrected Volume (mL) ± SE
	Controls	Premanifest HD	Controls	Premanifest HD	Controls	Premanifest HD
Caudate nucleus	0.023 ± 0.002	0.048 ± 0.004^{^a,^b,^c}	43.69 ± 0.88	49.35 ± 1.63^{^c,^d}	7.1 ± 0.8	5.4 ± 0.9^{^a,^b}
Putamen	0.029 ± 0.002	0.067 ± 0.007^{^a,^b,^c}	52.59 ± 1.39	64.21 ± 2.55^{^b,^c,^d}	8.6 ± 0.7	6.1 ± 1.3^{^a,^b}
Globus pallidus	0.091 ± 0.005	0.117 ± 0.007^{^d}	84.48 ± 2.64	92.75 ± 3.35	2.8 ± 0.4	3.0 ± 0.8
Thalamus	−0.024 ± 0.002	−0.021 ± 0.002	40.22 ± 0.70	40.07 ± 0.79	13.8 ± 0.8	12.9 ± 1.5
Amygdala	−0.018 ± 0.003	−0.023 ± 0.002	29.82 ± 0.78	31.59 ± 1.64	1.9 ± 0.6	2.0 ± 0.7
Hippocampus	−0.017 ± 0.001	−0.021 ± 0.002^{^d}	31.32 ± 0.54	30.47 ± 1.12	6.1 ± 0.9	5.7 ± 1.1
Substantia nigra	0.080 ± 0.004	0.057 ± 0.009^{^e}	75.45 ± 2.68	70.62 ± 3.05	1.3 ± 0.4	1.3 ± 0.4
Red nucleus	0.076 ± 0.005	0.066 ± 0.009	65.30 ± 2.71	67.00 ± 2.47	0.5 ± 0.2	0.6 ± 0.1

↵a Significant difference with P < .001.
↵b Significant correlation with CAPs score in subjects with premanifest HD.
↵c Significant correlation with ROI volume in subjects with premanifest HD.
↵d Significant difference with P < .01.
↵e Significant difference between controls and premanifest HD with P < .05.